ROS1 and non-small cell lung carcinoma: Antibody-drug conjugates represent an emerging therapeutic modality that has demonstrated some activity in patients with fusion oncogene-driven (including ROS1+) NSCLC, with responses observed irrespective of the mechanism of TKI resistance.104–106 Further development of resistance mechanism-agnostic treatment strategies for patients with ROS1 TKI-resistant NSCLC is warranted.